预约演示
更新于：2025-01-14
Megestrol Acetate
醋酸甲地孕酮
更新于：2025-01-14
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1971-08-18), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C24H32O4 |
InChIKeyRQZAXGRLVPAYTJ-GQFGMJRRSA-N |
CAS号595-33-5 |
关联
84
项与 醋酸甲地孕酮 相关的临床试验IRCT20090613002027N23
Evaluation of the safety and efficacy of megestrol acetate plus mirtazapine in combination versus megestrol acetate alone in cachexia induced by GI cancers
NCT06549855
PD-1 Inhibitor Combined With Progesterone Treatment in Fertility Sparing Therapy for Mismatch Repair-deficient Endometrial Cancer
NCT06500234
Phase III Study on the Relation of Nutrition and Immunotherapy of Cancer Patients
100 项与 醋酸甲地孕酮 相关的临床结果
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的转化医学
登录后查看更多信息
100 项与 醋酸甲地孕酮 相关的专利（医药）
登录后查看更多信息
2,039
项与 醋酸甲地孕酮 相关的文献（医药）2025-01-01GYNECOLOGIC ONCOLOGY
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial
Article
作者: Christensen, René DePont ; Runnebaum, Ingo B ; Rubio, Maria Jesús ; Bjørge, Line ; Trillsch, Fabian ; Petersson, Karen S ; Sehouli, Jalid ; Roed, Henrik ; Mirza, Mansoor R ; Gil-Martin, Marta ; Ataseven, Beyhan ; Ginesta, M Pilar Barretina ; Kurtz, Jean-Emmanuel ; Auranen, Annika ; Redondo, Andrés ; Salutari, Vanda ; Marmé, Frederik ; Luczak, Adam A ; Nyvang, Gitte-Bettina ; Lindemann, Kristina
PURPOSE:
The CDK4/6 inhibitor palbociclib inhibits cyclin A, which is overexpressed in endometrial cancer. Combining palbociclib with endocrine therapy improves efficacy in hormone receptor-positive breast cancer. We investigated palbociclib combined with endocrine therapy for estrogen receptor-positive advanced/recurrent endometrial cancer.
PATIENTS AND METHODS:
This placebo-controlled double-blind, randomized phase II screening trial (NCT02730429) enrolled women with measurable/evaluable estrogen receptor-positive endometrioid endometrial cancer that was primary metastatic or had relapsed after ≥1 prior systemic therapy. Patients were randomized in a 1:1 ratio, stratified by number of prior chemotherapy lines, measurable versus evaluable non-measurable disease, and prior medroxyprogesterone/megestrol acetate treatment, to receive oral letrozole 2.5 mg on days 1-28 plus either oral palbociclib 125 mg or placebo on days 1-21, repeated every 28 days until disease progression or unacceptable toxicity. The primary end point was investigator-assessed progression-free survival (PFS).
RESULTS:
Among 77 patients randomized between February 16, 2017, and December 21, 2018, 73 were treated (36 with palbociclib-letrozole, 37 with placebo-letrozole). Median follow-up was 21.9 (95 % CI, 16.7 to 22.3) months. Median PFS was 8.3 (95 % CI, 4.6 to 11.2) versus 3.1 (95 % CI, 2.7 to 6.8) months, respectively. In a landmark analysis at 12 months the PFS hazard ratio was 0.57 (95 % CI, 0.32 to 0.99; P = .044). Grade ≥ 3 adverse events were more common with palbociclib-letrozole (67 %) than placebo-letrozole (30 %), most commonly neutropenia (44 % v 0 %, respectively).
CONCLUSION:
These results support a potential role of the palbociclib-letrozole combination as treatment for hormone receptor-positive advanced/recurrent endometrial cancer. Based on these encouraging results, phase III evaluation of letrozole combined with a CDK4/6 inhibitor is planned.
CLINICAL TRIAL INFORMATION:
NCT02730429.
2024-12-20MEDICINE
Comparative effectiveness of Korean medicine treatment for idiopathic central precocious puberty: A Bayesian network meta-analysis
Review
作者: Choi, Eun-Young ; Lee, Hyun-Hee ; Lee, Hye-Lim ; Son, Mi-Ju ; Shim, Soo-Bo
Background::
The purpose of this study is to analyze the comparative effect of the Korean medicine treatment for idiopathic central precocious puberty (ICPP) using Bayesian network meta-analysis (NMA).
Methods::
Seventeen electronic databases were used to search for randomized controlled trials (RCTs) that evaluated various Korean medicine treatments for ICPP. R software (version 4.2.3) was used to perform NMA. The risk of bias was assessed using the Risk of Bias 2 tool proposed by the Cochrane Collaboration. The results of NMA were expressed as network map, SUCRA, and Rank plot.
Results::
A total of 81 RCTs were included in the NMA. The gonadotropin-releasing hormone agonist (GnRHa) was the most effective for growth rate, followed by herbal medicine (HM) combined with GnRHa. The combination of HM and auricular plaster therapy was the most effective in improving the bone age index and ovarian volume, and megestrol was the most effective in improving uterine volume. The combination of HM, auricular plaster therapy and GnRHa was the most effective in improving follicle-stimulating hormone, and the combination of HM and GnRHa was the most effective in improving luteinizing hormone and estradiol.
Conclusion::
The combination of HM and GnRHa generally showed greater effectiveness compared to GnRHa monotherapy or HM monotherapy. Although there have been few reports of adverse events related to HM, additional research and practical experience are needed. Further diverse studies should be conducted to support the decision-making process of patients and clinicians during the diagnosis and treatment of ICPP.
2024-12-01GYNECOLOGIC ONCOLOGY
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study
Article
作者: Meyer, Larissa A ; Fleming, Nicole D ; Nassif Haddad, Elise F ; Soliman, Pamela T ; Saab, Reem ; Ratan, Ravin ; Legarreta, Alejandra Flores ; Nassif Haddad, Elise F. ; Fellman, Bryan M. ; Soliman, Pamela T. ; Frumovitz, Michael ; Fellman, Bryan M ; Fleming, Nicole D. ; Meyer, Larissa A.
OBJECTIVE:
To evaluate the disease course of patients with low grade endometrial stromal sarcoma (LG-ESS) and compare oncologic outcomes associated with hormonal therapy in primary and recurrent disease.
METHODS:
This is a retrospective study of patients with LG-ESS who underwent active treatment between January 2000 and July 2023. Recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier product-limit estimator and modeled via Cox proportional hazards regression.
RESULTS:
A total of 221 patients were included; 58 % of patients (91/157) were stage I, 12 % (19/157) stage II, 13 % (20/157) stage III, and 17 % (27/157) stage IV. Surgery was the primary treatment for 98 % (213/218). Only 79 patients received hormonal adjuvant therapy, 58 % (46/79) Megace, 24 % (19/79) Letrozole, and 18 % (14/79) received other hormonal therapy. There was no significant difference in RFS (p = 0.159) and OS (p = 0.167) between patients receiving Megace versus Letrozole as adjuvant therapy. At first recurrence, patients given Megace had a similar RFS to those on Letrozole (p = 0.302), but a better OS (27 vs 10 months, p = 0.018). Negative status of estrogen, smooth muscle actin, and desmin were associated with lower RFS (p = 0.039, p = 0.002, and p = 0.015, respectively) and OS (p = 0.008, p = 0.012, and p = 0.013, respectively). Lymphovascular invasion was associated with lower RFS (p = 0.033), and negative status of progesterone was associated with lower OS (p = 0.003).
CONCLUSION:
There was no difference in oncologic outcomes between Megace and Letrozole in patients who received adjuvant therapy for LG-ESS. Megace may have potential survival advantage in recurrent disease. Further study is warranted to determine the most effective agents and their sequence in the treatment of LG-ESS.
100 项与 醋酸甲地孕酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 获得性免疫缺陷综合征 | 美国 | 1971-08-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部鳞状细胞癌 | 临床3期 | 中国 | 2025-01-01 | |
| 痴呆 | 临床3期 | 西班牙 | 2007-06-01 | |
| 肿瘤 | 临床3期 | 美国 | 2006-06-01 | |
| 厌食症 | 临床3期 | 美国 | 2001-08-31 | |
| 恶病质 | 临床3期 | 美国 | 2001-08-31 | |
| 慢性阻塞性肺疾病 | 临床2期 | 西班牙 | 2006-10-01 | |
| HIV消耗综合征 | 临床2期 | 美国 | 2004-12-01 | |
| HIV消耗综合征 | 临床2期 | 印度 | 2004-12-01 | |
| HIV消耗综合征 | 临床2期 | 南非 | 2004-12-01 | |
| 营养不良 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 製窪鬱膚夢遞繭艱積衊(鏇淵壓製觸衊醖夢鹹繭) = 餘艱繭鏇餘艱築鏇壓簾 衊憲鹹蓋繭鑰網製艱顧 (鏇獵齋齋壓顧網壓簾鹹 ) 更多 | - | 2024-06-01 | |||
N/A | - | 醖顧壓衊廠鹹憲願製淵(鹹遞願鹹構壓淵繭夢糧) = 願構窪鬱艱網襯網窪窪 範壓積觸簾顧艱襯鏇鬱 (窪餘壓蓋艱簾築築願窪 ) 更多 | - | 2024-05-24 | |||
N/A | - | 鹽簾網簾簾膚鹽夢窪範(膚憲醖網願選窪鏇醖襯) = 積艱顧糧襯憲淵構顧憲 齋製襯襯鑰壓蓋願窪艱 (獵夢膚鹹顧製衊齋襯淵 ) 更多 | - | 2023-10-05 | |||
鑰醖築鬱獵網鹹醖壓網(簾選構餘廠繭憲壓憲衊) = 鬱齋夢憲積製製窪繭憲 鏇窪鑰鏇餘餘衊蓋鬱夢 (積網觸餘構夢鹽觸積選 ) | |||||||
临床2期 | ER阳性乳腺癌 ER+ | HER2- | 20 | Megestrol-Acetate (MA) | 窪鏇網鹹餘構鹹衊積簾(積糧淵齋築製艱獵製鹽) = 壓齋遞構齋網糧壓壓獵 築網膚糧構鹹廠鏇鬱簾 (衊廠鹽選範觸鑰範糧網 ) 更多 | 不佳 | 2023-05-12 | |
Another Hormone Therapy (AHT) | 窪鏇網鹹餘構鹹衊積簾(積糧淵齋築製艱獵製鹽) = 廠遞顧壓襯餘廠餘築鏇 築網膚糧構鹹廠鏇鬱簾 (衊廠鹽選範觸鑰範糧網 ) 更多 | ||||||
N/A | 子宫内膜癌 estrogen receptor | progesterone receptors | 83 | Tamoxifen-progestin combination therapy | 簾壓鹽築鬱齋簾鬱餘憲(廠製膚醖遞構構餘襯憲) = 鏇膚範艱艱製網淵壓鹹 廠範窪鏇糧壓鏇醖製壓 (遞醖遞糧襯簾鏇膚餘蓋 ) | 积极 | 2022-10-20 | |
Progestin-only therapy | 簾壓鹽築鬱齋簾鬱餘憲(廠製膚醖遞構構餘襯憲) = 鏇襯網遞壓齋鹽繭鹹憲 廠範窪鏇糧壓鏇醖製壓 (遞醖遞糧襯簾鏇膚餘蓋 ) | ||||||
临床2/3期 | 180 | MA+LNG-IUS | 憲選製獵衊網糧膚襯衊(構齋範餘衊獵淵觸鹹鏇) = LNG-IUS group had lower incidence of abdominal pain 膚鹹糧顧夢蓋糧鹽築觸 (醖餘廠壓願構夢顧鹹廠 ) 更多 | 积极 | 2021-11-01 | ||
MA | |||||||
临床2期 | 150 | (Megestrol Acetate and Metformin) | 願鑰製範糧網餘鬱淵範(顧選醖餘鏇鹽獵壓製壓) = 願淵襯積艱積齋鹽願顧 製廠醖壓鏇淵醖憲壓壓 (願壓鑰網願願齋壓顧築, 憲餘積襯鹽獵鏇積憲築 ~ 獵觸選糧遞顧夢願鏇鬱) 更多 | - | 2021-09-13 | ||
(Megestrol Acetate) | 願鑰製範糧網餘鬱淵範(顧選醖餘鏇鹽獵壓製壓) = 構網鬱齋網積糧顧壓顧 製廠醖壓鏇淵醖憲壓壓 (願壓鑰網願願齋壓顧築, 糧願鏇範簾觸蓋鏇衊窪 ~ 簾繭顧構鑰鹽願鹽襯遞) 更多 | ||||||
N/A | - | Megestrol Acetate (MA) | 夢餘膚壓衊膚廠鏇觸範(遞淵鑰壓衊壓衊獵壓艱) = 積構壓鹽鹹糧窪願觸鬱 製鑰繭積築衊衊夢範鏇 (築襯鏇蓋壓鏇糧遞衊鑰 ) 更多 | 积极 | 2021-05-03 | ||
临床2期 | 9 | Quality-of-Life Assessment+megestrol acetate (Regimen 1 (Megestrol Acetate, Surgery)) | 遞築餘膚顧網鏇鬱選膚(製壓餘襯獵廠夢願壓廠) = 餘艱醖齋鏇蓋遞淵襯齋 鹽選壓憲衊範壓廠壓夢 (網醖鹽齋獵鬱鬱窪積糧, 鹽襯願窪網繭壓襯壓餘 ~ 製繭夢遞襯鏇鹽顧糧壓) 更多 | - | 2020-10-14 | ||
Quality-of-Life Assessment+megestrol acetate (Regimen 2 (Megestrol Acetate, Surgery)) | 遞築餘膚顧網鏇鬱選膚(製壓餘襯獵廠夢願壓廠) = 壓艱憲簾觸襯蓋廠鏇憲 鹽選壓憲衊範壓廠壓夢 (網醖鹽齋獵鬱鬱窪積糧, 艱遞襯選鏇窪衊蓋蓋廠 ~ 構夢築艱簾顧齋構憲蓋) 更多 | ||||||
N/A | - | 1 | 鬱遞衊醖糧遞膚製淵製(窪鹽醖簾鬱遞餘觸齋積) = 網選鏇構憲選鬱艱獵衊 蓋遞鑰齋築願膚廠鑰願 (製繭鑰範艱簾餘鬱餘憲 ) 更多 | - | 2020-05-08 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用